Dependent Insulinotropic Receptor Market -Industry News, Applications and Trends
The "Global Dependent Insulinotropic Receptor Market" is predicted to reach a high CAGR during the forecast period (2021-2028)
(EMAILWIRE.COM, October 05, 2021 )
Market Overview
The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the GIPR gene. GIP-R is a member of the 7-transmembrane protein family, a class of G protein.
View full report: https://bit.ly/3FgmllH
Market Dynamics
The global dependent insulinotropic receptor market growth is driven by the increasing incidence of diabetes population, obesity, due to sedentary lifestyles, growing geriatric population and unhealthy dietary habits, a greater number of individuals are suffering from chronic lifestyle diseases.
Increasing incidence of diabetes population globally, is expected to drive the global dependent insulinotropic receptor market growth
Diabetes is a chronic, life-threatening disease with an unknown cure. It has been emerged as a global epidemic and affected millions globally. Furthermore, Type 1 diabetes is caused due to an immune system malfunction.
Hence, Type 1 diabetes can be characterized most by insulin-requiring. The number of people who have diabetes in regions such as MEA and APAC is increasing, which in turn is propelling the demand for the dependent insulinotropic receptor market. For instance, as per the International Diabetes Federation 2017, more than 72,946,400 new cases of diabetes were diagnosed in India.
At present, China has the highest number of diabetes patients in the world. In addition, the prevalence of diabetes in China has risen substantially over the past decade. For instance, according to WHO, in 2020, China had about 126.80 million diabetic patients, and this number is expected to reach 138.42 million by the end of 2026.
China's urbanization and growing living standards, leading to reduced physical activity and unhealthy diets, are the significant factors behind the high rate of diabetes. In 2020, China accounted for 9.8% of Type 1 diabetes patients of the total diabetes population.
The increasing incidence of obesity population globally is expected to drive the global dependent insulinotropic receptor market growth
Obesity is a major factor leading to diabetes. According to the WHO, in 2016, over 1.9 billion adults were overweight, of which around 650 million people were obese. Risk factors, like obesity and overweight, are leading to an increase in the incidence of diabetes.
Therefore, risk factors such as smoking, overweight, obesity, and high cholesterol levels are expected to boost the prevalence of diabetes.
Segment Analysis
By Product type
• DA-1241
• GSK-2041706
• HD-0471042
• HD-0471953
By Application
• Type 2 Diabetes
• Obesity
• Chronic Obstructive Pulmonary Disease (COPD)
Download free sample: https://bit.ly/3ovHHFJ
Geographical Analysis
North America region holds the largest market share of global dependent insulinotropic receptor market
In 2020, the United States accounted for a majority of the revenue share (about 96%) in the market, mainly due to the increasing diabetic population in the country. According to a recent survey, about 9.4% of the total US population is diabetic, and about 1.75 million Americans are diagnosed with diabetes every year.
Type 2 diabetes is increasingly prevalent but also largely preventable. According to the Centers for Disease Control and Prevention (CDC)Trusted Source, type 2 diabetes accounts for about 90 to 95 percent of all diagnosed cases of diabetes in adults. The growing research and developments, rising investments are the major factors driving the market. For instance,
Competitive Landscape
The global dependent insulinotropic receptor market is moderately competitive with the presence of global companies.
Some of the key players which are contributing to the growth of the market include Amgen Inc, Arena Pharmaceuticals Inc, CymaBay Therapeutics Inc, Dong-A Socio Holdings Co Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hyundai Pharmaceutical Co Ltd, Kowa Co Ltd, Merck and Co Inc, Novartis AG, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Co Ltd, Yuhan Corp.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.
Related Topic's
Insulinoma Treatment Market, Insulation Materials Market, Insulin Glargine Market, Disposable Insulin Pumps Market, Insulin Pen Market
Market Overview
The gastric inhibitory polypeptide receptor (GIP-R), also known as the glucose-dependent insulinotropic polypeptide receptor, is a protein that in humans is encoded by the GIPR gene. GIP-R is a member of the 7-transmembrane protein family, a class of G protein.
View full report: https://bit.ly/3FgmllH
Market Dynamics
The global dependent insulinotropic receptor market growth is driven by the increasing incidence of diabetes population, obesity, due to sedentary lifestyles, growing geriatric population and unhealthy dietary habits, a greater number of individuals are suffering from chronic lifestyle diseases.
Increasing incidence of diabetes population globally, is expected to drive the global dependent insulinotropic receptor market growth
Diabetes is a chronic, life-threatening disease with an unknown cure. It has been emerged as a global epidemic and affected millions globally. Furthermore, Type 1 diabetes is caused due to an immune system malfunction.
Hence, Type 1 diabetes can be characterized most by insulin-requiring. The number of people who have diabetes in regions such as MEA and APAC is increasing, which in turn is propelling the demand for the dependent insulinotropic receptor market. For instance, as per the International Diabetes Federation 2017, more than 72,946,400 new cases of diabetes were diagnosed in India.
At present, China has the highest number of diabetes patients in the world. In addition, the prevalence of diabetes in China has risen substantially over the past decade. For instance, according to WHO, in 2020, China had about 126.80 million diabetic patients, and this number is expected to reach 138.42 million by the end of 2026.
China's urbanization and growing living standards, leading to reduced physical activity and unhealthy diets, are the significant factors behind the high rate of diabetes. In 2020, China accounted for 9.8% of Type 1 diabetes patients of the total diabetes population.
The increasing incidence of obesity population globally is expected to drive the global dependent insulinotropic receptor market growth
Obesity is a major factor leading to diabetes. According to the WHO, in 2016, over 1.9 billion adults were overweight, of which around 650 million people were obese. Risk factors, like obesity and overweight, are leading to an increase in the incidence of diabetes.
Therefore, risk factors such as smoking, overweight, obesity, and high cholesterol levels are expected to boost the prevalence of diabetes.
Segment Analysis
By Product type
• DA-1241
• GSK-2041706
• HD-0471042
• HD-0471953
By Application
• Type 2 Diabetes
• Obesity
• Chronic Obstructive Pulmonary Disease (COPD)
Download free sample: https://bit.ly/3ovHHFJ
Geographical Analysis
North America region holds the largest market share of global dependent insulinotropic receptor market
In 2020, the United States accounted for a majority of the revenue share (about 96%) in the market, mainly due to the increasing diabetic population in the country. According to a recent survey, about 9.4% of the total US population is diabetic, and about 1.75 million Americans are diagnosed with diabetes every year.
Type 2 diabetes is increasingly prevalent but also largely preventable. According to the Centers for Disease Control and Prevention (CDC)Trusted Source, type 2 diabetes accounts for about 90 to 95 percent of all diagnosed cases of diabetes in adults. The growing research and developments, rising investments are the major factors driving the market. For instance,
Competitive Landscape
The global dependent insulinotropic receptor market is moderately competitive with the presence of global companies.
Some of the key players which are contributing to the growth of the market include Amgen Inc, Arena Pharmaceuticals Inc, CymaBay Therapeutics Inc, Dong-A Socio Holdings Co Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hyundai Pharmaceutical Co Ltd, Kowa Co Ltd, Merck and Co Inc, Novartis AG, Taisho Pharmaceutical Holdings Co Ltd, Takeda Pharmaceutical Co Ltd, Yuhan Corp.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.
Related Topic's
Insulinoma Treatment Market, Insulation Materials Market, Insulin Glargine Market, Disposable Insulin Pumps Market, Insulin Pen Market
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results